Generic-drug maker Barr Pharmaceuticals will pay $5.9 million to end an antitrust lawsuit filed by 34 states over claims that it received $20 million to hold off on marketing its version of Warner Chilcott Ltd.'s Ovcon, an oral contraceptive. Under the terms of the settlement, Barr is prohibited from entering into noncompetition agreements with firms that market brand name treatments for the next decade. A spokeswoman for Barr denied any wrongdoing, saying that the company still deems the deal with Warner Chilcott "legal, legitimate and pro-competitive."

Related Summaries